|
|
|
4MIRA INFORM REPORT
|
Report No. : |
492255 |
|
Report Date : |
17.02.2018 |
IDENTIFICATION DETAILS
|
Name : |
DAEWOONG
PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
244,
Galmachi-Ro, Jungwon-Gu, Seongnam-Si, Gyeonggi-Do, Korea 13211 |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Financials (as on) : |
30.09.2017 |
|
|
|
|
Date of Incorporation : |
02.10.2002 |
|
|
|
|
Com. Reg. No.: |
124-86-01143 |
|
|
|
|
Legal Form : |
Listed Company |
|
|
|
|
Line of Business : |
Manufacture of Medicinal Chemicals and Antibiotics. |
|
|
|
|
No. of Employees : |
1,501 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A+ |
|
Credit Rating |
Explanation |
Rating Comments |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.06.2017) |
Current Rating (30.09.2017) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
SOUTH KOREA - ECONOMIC OVERVIEW
After emerging from the 1950-53 war with North Korea, South Korea emerged as one of the 20th century’s most remarkable economic success stories, becoming a developed, globally connected, high-technology society within decades. In the 1960s, GDP per capita was comparable with levels in the poorest countries in the world. In 2004, South Korea joined the trillion-dollar club of world economies.
Beginning in the 1960s under President PARK Chung-hee, the government promoted the import of raw materials and technology, encouraged saving and investment over consumption, kept wages low, and directed resources to export-oriented industries that remain important to the economy to this day. Growth surged under these policies, and frequently reached double-digits in the 1960s and 1970s. Growth gradually moderated in the 1990s as the economy matured, but remained strong enough to propel South Korea into the ranks of the advanced economies of the OECD by 1997. These policies also led to the emergence of family-owned chaebol conglomerates such as Daewoo, Hyundai, and Samsung, which retained their dominant positions even as the government loosened its grip on the economy amid the political changes of the 1980s and 1990s.
The Asian financial crisis of 1997-98 hit South Korea’s companies hard because of their excessive reliance on short-term borrowing, and GDP ultimately plunged by 7% in 1998. South Korea tackled difficult economic reforms following the crisis, including restructuring some chaebols, increasing labor market flexibility, and opening up to more foreign investment and imports. These steps lead to a relatively rapid economic recovery. South Korea also began expanding its network of free trade agreements to help bolster exports, and has since implemented 16 free trade agreements covering 58 countries—including the United State and China—that collectively cover more than three-quarters of global GDP.
In 2017, the election of President MOON Jae-in brought a surge in consumer confidence, in part, because of his successful efforts to increase wages and government spending. These factors combined with an uptick in export growth to drive real GDP growth to more than 3%, despite disruptions in South Korea’s trade with China over the deployment of a US missile defense system in South Korea.
In 2018 and beyond, South Korea will contend with gradually slowing economic growth - in the 2-3% range - not uncommon for advanced economies. This could be partially offset by efforts to address challenges arising from its rapidly aging population, inflexible labor market, continued dominance of the chaebols, and heavy reliance on exports rather than domestic consumption. Socioeconomic problems also persist, and include rising inequality, poverty among the elderly, high youth unemployment, long working hours, low worker productivity, and corruption.
|
Source
: CIA |
Basic Information
|
Company Name |
DAEWOONG
PHARMACEUTICAL CO., LTD. |
|
Registered Address |
244,
Galmachi-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea (Old Address
System : 223-23, Sangdaewon-dong, Jungwon-gu, Seongnam-si, Gyeonggi-do,
Korea) |
|
Building |
-- |
|
Zip Code |
13211 |
|
Tel |
+82-31-741-7700~4 |
|
Fax |
+82-31-749-5535 |
|
E-mail |
global@daewoong.co.kr;ksyun@daewoong.co.kr;stomeve@daewoong.co.kr; jskimao@daewoong.co.kr |
|
Website |
www.daewoong.co.kr |
|
Trading Address |
12, Bongeunsa-ro 114-gil, Gangnam-gu, Seoul,
Korea (Old Address System : 163-3, Samsung-dong,
Gangnam-gu, Seoul, Korea) |
|
Tel |
+82-2-550-8800 |
|
Fax |
+82-2-550-8400 |
|
Other Address-R&D Center |
72, Dugye-ro, Pogok-eup, Cheoin-gu,
Yongin-si, Gyeonggi-do, Korea (Old Address System : 501-2, Samgye-ri,
Pogok-myon, Yongin-si, Gyeonggi-do, Korea) |
|
Tel |
+82-31-270-8300 |
|
Fax |
+82-31-333-1002 |
|
Other Address-Hyangnam Factory |
35-14, Jeyakgongdan 4-gil, Hyangnam-eup,
Hwaseong-si, Gyeonggi-do, Korea (Old Address System : 906-10,
Sangshin-ri, Hyangnam-myon, Hwasung-si, Gyeonggi-do, Korea) |
|
Tel |
+82-31-353-5911~5 |
|
Fax |
+82-31-353-5916 |
|
Other Address-Seongnam Factory |
244, Galmachi-ro, Jungwon-gu, Seongnam-si,
Gyeonggi-do, Korea (Old Address System : 223-23,
Sangdaewon-dong, Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea) |
|
Tel |
+82-31-741-7700~4 |
|
Fax |
+82-31-749-5535 |
|
Other Address-Anseong Factory |
69, Gongdan 1-ro, Anseong-si, Gyeonggi-do,
Korea (Old Address System : 54-7 Singeonji-dong
,Anseong-si, Gyeonggi-do, Korea) |
|
Tel |
+82-31-678-1800 |
|
Fax |
+82-31-678-1866 |
|
Other Address-Osong Factory |
1, Osongsaengmyeong 2-ro, Osong-eup,
Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Korea (Old Address System : 689, Yeonje-ri,
Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Korea) |
|
Tel |
+82-43-249-2600 |
|
Fax |
+82-43-249-2935 |
|
Type |
Export/Import |
|
Industry |
Manufacture of Medicinal Chemicals and Antibiotics |
|
Main Business |
Medicine |
|
Sub
Business |
|
|
Established (mm/dd/yyyy) |
10/02/2002 |
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Antiulcer and related gastrointestinal GI drugs(51171900) |
|
Sell |
Antianemic drugs(51131500) |
|
Sell |
Antibiotics(51101500) |
|
Sell |
Drugs used for respiratory tract disorders(51161700) |
|
Sell |
Mouth fresheners(53131509) |
|
Sell |
Cough and cold and antiallergy products(51161800) |
|
Sell |
Hormones and antihormones(51111800) |
|
Buy |
Nonsteroidal anti inflammatory drugs NSAIDs(51142100) |
|
Buy |
Dexchlorpheniramine maleate(51161603) |
|
Buy |
Acetaminophen(51142001) |
|
Buy |
Antifungal drugs(51101800) |
|
Buy |
Ipratropium bromide(51161705) |
|
Buy |
Preservatives(12164501) |
|
Buy |
Ephedrine(51151741) |
|
Buy |
Mefenamic acid(51142012) |
|
Buy |
Ibuprofen(51142106) |
CEO’s
|
Name |
Yoon Jae-Seung |
|
Date of Birth |
11/09/1962 |
|
Title |
Chairman & CEO |
|
Nationality |
Korean |
Profiles
|
Capital (KRW) |
28,966,437,500 |
|||||||||||||||||||||
|
Employees |
1,501 |
|||||||||||||||||||||
|
Formation |
Listed Company (Korea Stock Exchange : 069620) as of 11/01/2002 A Company of DAEWOONG GROUP |
|||||||||||||||||||||
|
Bank Details |
Shinhan Bank KEB Hana Bank Woori Bank Citibank, Korea |
|||||||||||||||||||||
|
Corporate Registered No. |
134811-0075342 |
|||||||||||||||||||||
|
Business Registered No. |
124-86-01143 |
|||||||||||||||||||||
|
Permit & Licenses |
2003 ISO 14001 (Hyangnam Factory) Mail Order License No.: 2007-Gyeonggi
Seongnam-0751 Int’l Trade No.: 45101917 |
|||||||||||||||||||||
|
Shareholder Position |
|
|||||||||||||||||||||
|
Company History |
10/02/2002 Incorporated as the present name
after spin-off from DAEWOONG CO., LTD.(110111-2857146) 05/30/2003 Moved to the present HQ address
from 906-10, Sangshin-ri, Hyangnam-myon, Hwasung-si,
Gyeonggi-do, Korea 01/01/2013 Increased capital to 28,966,437,500
KRW from 28,214,920,000 KRW |
Management
|
Job Description |
Name |
Nationality |
Date of Birth |
Inauguration Date |
|
Chairman & CEO |
Yoon Jae-Seung |
Korean |
11/09/1962 |
06/28/2012 |
|
President & CEO |
Lee Jong-Wook |
Korean |
03/10/1949 |
03/16/2012 |
|
Managing Director |
Noh Gab-Yong |
Korean |
06/27/1966 |
03/15/2013 |
|
Outside Director |
Yang Yun-Seon |
Korean |
12/23/1964 |
03/24/2017 |
|
Outside Director |
Shim Chang-Gu |
Korean |
07/21/1948 |
03/20/2015 |
|
Auditor |
Lee Chung-Woo |
Korean |
03/29/1966 |
03/24/2017 |
Financials
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
09/2017 |
653,189,977,053 |
1,058,356,136,588 |
29,242,222,066 |
|
2016 |
794,009,800,581 |
1,015,246,926,534 |
32,974,250,663 |
|
2015 |
800,517,043,196 |
819,336,096,050 |
49,232,912,266 |
|
2014 |
727,222,609,723 |
678,153,978,628 |
31,792,910,393 |
|
2013 |
674,867,033,169 |
572,053,855,805 |
58,673,000,967 |
|
2012 |
664,648,216,977 |
477,119,010,069 |
34,552,757,376 |
|
2011 |
706,643,346,720 |
493,208,780,203 |
51,763,399,907 |
Financial Description
|
Authorized Capital(KRW) |
80,000,000,000 |
|
Paid-Up Capital(KRW) |
28,966,437,500 |
|
Total Issued Shares |
11,586,575 |
|
Balance Sheet |
|||
|
Unit : Korean Won |
01/01/2017~09/30/2017 |
As of 12/31/2016 |
As of 12/31/2015 |
|
Total
Assets |
1,058,356,136,588 |
1,015,246,926,534 |
819,336,096,050 |
|
Current Assets |
376,160,247,352 |
403,022,674,603 |
341,732,277,445 |
|
Cash
& Cash Equivalents |
54,924,125,350 |
55,645,111,352 |
33,617,234,394 |
|
Current
Financial Instruments |
284,800,000 |
36,009,315,412 |
49,722,959,250 |
|
Trade
Receivables & Other Receivables |
165,079,715,597 |
163,495,061,683 |
123,219,873,351 |
|
Inventories |
151,091,507,454 |
140,581,638,565 |
122,636,448,382 |
|
Other
Current Assets |
4,780,098,951 |
7,291,547,591 |
12,535,762,068 |
|
Non-Current Assets |
682,195,889,236 |
612,224,251,931 |
477,603,818,605 |
|
Non-Current
Financial Instruments |
10,500,000 |
10,500,000 |
|
|
Long-Term
Trade Receivables & Other Receivables |
6,856,398,895 |
6,948,658,091 |
2,394,347,916 |
|
Marketable
Financial Instruments |
5,327,311,693 |
5,237,005,133 |
7,394,919,166 |
|
Investment_Related
Companies |
1,319,085,500 |
1,319,085,500 |
1,319,085,500 |
|
Investment_Subsidiaries |
181,163,406,001 |
168,779,985,001 |
163,311,235,628 |
|
Tangibles |
305,146,741,504 |
279,617,017,545 |
184,468,054,304 |
|
Investment_Real
Estates |
96,734,396,634 |
97,747,713,839 |
84,456,035,355 |
|
Intangibles |
78,409,382,913 |
46,132,462,460 |
30,495,222,386 |
|
Other
Non-Current Assets |
526,264,638 |
526,264,638 |
543,576,209 |
|
Deferred
Income Tax Assets |
6,702,401,458 |
5,905,559,724 |
1,219,586,470 |
|
Other
Financial Assets |
|
|
2,001,755,671 |
|
Total Liabilities |
517,577,899,661 |
497,586,842,045 |
326,641,992,146 |
|
Current Liabilities |
311,412,724,069 |
202,360,569,438 |
132,835,285,437 |
|
Trade
Payables & Other Payables |
81,970,495,572 |
78,727,414,094 |
63,881,328,007 |
|
Short-Term
Borrowings |
6,290,673,137 |
5,370,599,208 |
4,980,878,580 |
|
Current
Portion of Debentures |
189,892,038,668 |
99,882,352,269 |
39,962,572,193 |
|
Deferred
Income Tax Credit |
8,114,291,654 |
4,204,441,354 |
7,228,889,492 |
|
Other
Current Financial Debts |
3,701,815,776 |
3,052,772,204 |
3,281,159,695 |
|
Other
Current Liabilities |
590,329,162 |
373,728,038 |
472,506,750 |
|
Deferred
Income |
20,853,080,100 |
10,749,262,271 |
13,027,950,720 |
|
Non-Current Liabilities |
206,165,175,592 |
295,226,272,607 |
193,806,706,709 |
|
Long-Term
Trade Payables & Other Payables |
4,316,465,433 |
4,372,047,393 |
4,396,372,353 |
|
Debentures |
199,543,797,231 |
289,164,854,306 |
189,410,334,356 |
|
Other
Non-Current Liabilities |
2,304,912,928 |
1,689,370,908 |
0 |
|
Capital Stock |
28,966,437,500 |
28,966,437,500 |
28,966,437,500 |
|
Others |
56,161,123,185 |
56,092,670,813 |
56,876,331,891 |
|
Profit
Surplus |
455,650,676,242 |
432,600,976,176 |
406,851,334,513 |
|
Total
Equity |
540,778,236,927 |
517,660,084,489 |
492,694,103,904 |
|
Liab.
& Shareholder’s Equity |
1,058,356,136,588 |
1,015,246,926,534 |
819,336,096,050 |
|
Income Statement |
|||
|
Unit : Korean Won |
01/01/2017~09/30/2017 |
As of 12/31/2016 |
As of 12/31/2015 |
|
Sales |
653,189,977,053 |
794,009,800,581 |
800,517,043,196 |
|
Cost
of Sold Goods |
381,021,949,310 |
464,768,049,177 |
516,417,872,098 |
|
Gross
Profit |
272,168,027,743 |
329,241,751,404 |
284,099,171,098 |
|
Selling
& Admin. Expenses |
95,847,267,611 |
293,852,577,163 |
229,026,093,919 |
|
Operating
Income |
38,279,221,344 |
35,389,174,241 |
55,073,077,179 |
|
Other
Income |
15,955,821,831 |
4,892,432,694 |
4,996,669,839 |
|
Other
Expenses |
9,014,372,758 |
2,773,047,334 |
760,959,441 |
|
Finance
Income |
3,078,060,244 |
7,623,798,607 |
5,991,068,713 |
|
Finance
Expenses |
9,239,714,872 |
9,929,631,522 |
6,016,004,466 |
|
Income
Before Taxes |
39,059,015,789 |
35,202,726,686 |
59,283,851,824 |
|
Income
Taxes Expenses |
9,816,793,723 |
2,228,476,023 |
10,050,939,558 |
|
Net
Income |
29,242,222,066 |
32,974,250,663 |
49,232,912,266 |
|
Cash Flows |
|||
|
Unit : Korean Won |
01/01/2017~09/30/2017 |
As of 12/31/2016 |
As of 12/31/2015 |
|
Operating Activities Cash Flows |
50,601,960,462 |
13,710,904,112 |
37,597,461,933 |
|
Cash
Flows from Operating |
63,189,616,973 |
29,190,188,496 |
43,163,937,405 |
|
Net
Income |
29,242,222,066 |
32,974,250,663 |
49,232,912,266 |
|
Adjustment |
48,742,058,815 |
25,992,563,729 |
43,478,274,576 |
|
Changes
in Asset/ & Liability |
-14,794,663,908 |
-29,776,625,896 |
-49,547,249,437 |
|
Interests
Received |
923,143,867 |
1,302,898,282 |
2,999,348,595 |
|
Interests
Paid |
-6,785,161,033 |
-7,093,477,837 |
-4,576,356,032 |
|
Income
Taxes |
-6,725,639,345 |
-9,688,704,829 |
-3,989,468,035 |
|
Cash
Flows from Investing |
-45,493,028,816 |
-143,849,637,396 |
-123,938,469,834 |
|
Cash
Flows from Financing |
-5,358,777,504 |
152,238,125,154 |
84,976,626,734 |
|
Increase/Decrease
in Cash |
-720,986,002 |
22,027,876,958 |
-1,204,039,964 |
|
Cash
at the Beginning of Year |
55,645,111,352 |
33,617,234,394 |
34,821,274,358 |
|
Cash
at the End of Year |
54,924,125,350 |
55,645,111,352 |
33,617,234,394 |
Products, Technologies, Services Description
|
Main Products & Services |
PHARMACEUTICAL PRODUCTS Bone & Joint disease Cardiovascular(CV) Central Nervous System(CNS) Dermatology Gastrointestinal(GI) Healthcare Infection & Respiratory Metabolic Disease(Endo) Oncology Others Brand Name : URSA, Luphere, Easyef |
Trade Partners & Competitors
|
Suppliers |
DAEWOONG BIO INC.(131112-0004827) CHEMIE S.P.A EISAI CO., LTD. DAINIPPON MERCK SANTE PRODESFARMA AG EDMOND PHARMA |
|
Customers |
DONGWHA PHARM IND CO., LTD.( 110111-0043870) |
|
Competitors |
DONGA PHARMACEUTICAL CO.,LTD.(110111-0017990) YUHAN CORPORATION(110111-0014409) HANMI PHAM CO., LTD.(134811-0003187) GREEN CROSS CORPORATION(110111-0109854) CHOONGWAE PHARMA CORP.(110111-0019342) |
Related Parties (Subsidiaries, Joint-Venture & Affiliates)
|
Affiliates |
DAEWOONG CO., LTD.(110111-2857146) DAEWOONG BIO INC. (131112-0004827) DAEWOONG INTERNATIONAL
CORP.(110111-0742985) R&P KOREA CO., LTD.(110111-0358021) DAEWOONG NUTRITIONS CO.,
LTD.(210111-0013294) DAEWOONG MANEGEMENT DEVELOPMENT
INSTITUTE(110111-0776463) EZMEDICOM CO., LTD.(110111-2063818) SANWOONG DEVELOPMENT CO.,
LTD.(110111-0978671) SANWOONG ENGINEERING CO.,
LTD.(134811-0034421) PHARMPAC CO., LTD.(134811-0048307) PAGE1 CO., LTD.(110111-1771040) DAEWOONG DEVELOPMENT CO.,
LTD.(131111-0083649) IDS&TRUST CO., LTD.(110111-1234006) BEST SYSTEM CO., LTD.(110111-1639850) JEJU MOVIELAND CO., LTD.(224111-0014832) BIO-SYNECTICS, INC.(110111-2943010) (20.82% held by the subject company) EPP MEDIA CO., LTD.(110111-3825069) (20.00% held by the subject company) MDWEL I&C CO., LTD.(110111-3716854) (50.00% held by the subject company) |
|
Overseas Branch |
CHINA BEIJING DAEWOONG PHARMACEUTICAL R&D
CENTER CO., LTD. ROOM 30506, UNIT C, GALAXY SOHO, A7,
XIAOPAIFANG STREET, DONGCHENG DISTRICT, BEIJING TEL +86-10-8478-2536 FAX +86-10-8478-2506 CHINA LIAONING DAEWOONG PHARMACEUTICAL CO.,LTD NO.5, CHUNAN STREET, SHIQIAOZI, XIHU
DISTRICT, BENXI, LIAONING POSTCODE : 117000 TEL +86-024-4556-8901 FAX +86-024-4556-8902 VIETNAM DAEWOONG PHARMACEUTICAL VIETNAM
REPRESENTATIVE OFFICE GREEN POWER BUILDING,12TH FLOOR, ROOM 1202
35 TON DUC THANG STREET, DISTRICT 1, HOCHIMINH CITY, VIETNAM TEL +84-283-910-2114~6 FAX +84-283-910-2117 THAILAND DAEWOONG PHARMACEUTICAL THAILAND CO., LTD. 1550 THANAPOOM TOWER, 14FL., NEW PETCHBURI
ROAD, MAKASAN, RATTHEWI, BANGKOK 10400 TEL +66 02-049-4401 FAX +66-02-049-4400 PHILIPPINES DAEWOONG PHARMACEUTICAL PHILIPPINES INC. UNIT 2811 28TH FLOOR ONE CORPORATE CENTER
JULIA VARGAS AVENUE COR. MERALCO AVENUE, PASIG CITY, PHILIPPINES TEL +63-2-635-5665 FAX +63-2-635-5541 INDONESIA PT DAEWOONG PHARMACEUTICAL COMPANY
INDONESIA 27TH UOB PLAZA UNIT 5, MH THAMRIN NO. 10,
JAKARTA 10230, INDONESIA TEL +62-21-3048-2269 FAX +62-813-3324-2224 INDONESIA PT DAEWOONG INFION JL. RAYA KASRI NO. 153, DESA TAWANGREJO
KEC. PANDAAN INDONESIA TEL +62-813-3324-2224 INDIA DAEWOONG PHARMACEUTICAL CO., LTD. INDIA
BRANCH OFFICE PLOT NO. 5A, APIIC, IE, PRASHANTH NAGAR,
KUKATPALLY, HYDERABAD–500072 TEL +91-40-4466-8800~07 FAX
+91-40-4466-8811 JAPAN DAEWOONG PHARMACEUTICAL JAPAN CO., LTD. KAL BLDG.,6F,1-9, HOMMACHI 3-CHOME,
CHUO-KU, OSAKA 541-0053 JAPAN TEL +81-6-6263-2241 FAX +81-6-6263-2240 USA DAEWOONG AMERICA INC. 1 CHURCH ST. STE 103, ROCKVILLE, MD 20850,
USA TEL +1-301-309-1958 FAX +1-301-309-1959 |
|
Subsidiary |
HEALIENCE CO., LTD.(110111-3265778) (75.97% held by
the subject company) PT. DEWOONG PHARMACEUTICAL(INDONESIA)CO., LTD. (100.0% held by the subject company) DAEWOONG AMERICA, INC.(USA) (100.0% held by the subject company) DAEWOONG PHARMACEUTICAL INDIA PVT., LTD.(INDIA) (100.0% held by the subject company) DAEWOONG PHARMACEUTICAL JAPAN CO., LTD.(JAPAN) (100.0% held by the subject company) DAEWOONG PHARM PHILIPPINES,INCORPORATED (100.0% held by the subject company) BEIJING DAEWOONG PHARMACEUTICAL R&D
CENTER CO., LTD.(CHINA) (100.0% held by the subject company) DAEWOONG PHARMACEUTICAL(THAILAND) CO., LTD. (100.0% held by the subject company) HANALL BIOPHARMA CO., LTD.(164111-0000397) (29.67% held by the subject company) |
|
Corporate Ownership |
DAEWOONG CO., LTD.(110111-2857146) |
|
Major Shareholders |
DAEWOONG CO., LTD.(110111-2857146) |
|
Cooperative Enterprise- Partnership |
-AMERICA BIO MED SCIENCES SUPERNUS ANTARES ELEISON STIEFEL EURAND VYRIX -FRANCE IPSEN MERCK SERONO ETHYPHARM ONXEO -SPAIN AIMIRAL ASTRAZENECA -SWITZERLAND TILLOTTS -DENMARK TAKEDA -SWEDEN MEDIVIR MEDA |
|
Cooperative Enterprise- Partnership |
-KOREA ASTRAZENECA MSD MERCK SERONO NOVARTIS JANSSEN UK CHEMIPHARM ILYANG PHARM MYUNGMOON PHARM MENARINI KYOWA HAKKO KIRIN SANDOZ TAKEDA ASTELLAS DAIICHI SANKYO CJ HEALTHCARE BORYUNG PHARM MERCK SERONO -ITALY ROTTA BRUSCHETTINI ITALIFARMACO RECIPHARM -JAPAN KAKEN SUMITOMO DAINIPPON MITSUBISHI TANABE DAJICHISANKYO SATO 3D-MATRIX EISAI KYOWA HAKKO KIRIN |
|
Cooperative Enterprise |
-
INSURED COMPANY DONGBU INSURANCE CO., LTD.(110111-0095285) SAMSUNG LIFE INSURANCE CO., LTD.(110111-0005953) KYOBO LIFE INSURANCE CO., LTD(110111-0014970) KOREA LIFE INSURANCE CO., LTD.(110111-0003204) |
Sales by Region (Activity & Markets)
|
Sales/ Unit :Mil
KRW |
09/2017 |
2016 |
2015 |
|
Export |
77,727 |
95,620 |
66,283 |
|
Domestic |
575,463 |
698,390 |
734,234 |
|
Total |
653,190 |
794,010 |
800,517 |
The Subject exports
to Taiwan, China, India, Malaysia, Philippines and Vietnam.
Court Action
There are 2 cases
filed as Defendant(s)/ Debtor(s)/ Respondent(s) as of 09/30/2017/
News Clipping
-----------
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 63.91 |
|
|
1 |
INR 90.31 |
|
Euro |
1 |
INR 80.17 |
|
KRW |
1 |
INR 0.060 |
Note:
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
PRA |
|
|
|
|
Report Prepared
by : |
NIT |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.